Introduction
Candida parapsilosis accounts for a signifi cant proportion of nosocomial infections, with an increasing prevalence in hospital settings. Earlier reports indicated that candidiasis caused by C. parapsilosis was associated with (a) the presence of indwelling devices, (b) the use of total parenteral nutrition (TPN) [1, 2] , and (c) the ability of this yeast to grow as biofi lms [3] .
Sequence analysis of internal transcribed spacer (ITS) subunit rRNA regions
Yeast genomic DNA for PCR amplifi cation was extracted using the High-Pure PCR Template Preparation Kit (Roche Diagnostic, Mannheim, Germany), according to the manufacturer ' s instructions. Sequencing of the 5.8S rRNA gene and the adjacent ITS1 and ITS2 regions was carried out. The identity of C. parapsilosis , C. orthopsilosis , and C. metapsilosis clinical isolates was confi rmed by DNA sequencing of the ITS1 and ITS4 regions of the 28S rRNA gene. ITS1 (forward, 5 ′ -TCC GTA GGT GAA CCT GCG G-3 ′ ) and ITS4 (reverse, 5 ′ -TCC TCC GCT TAT TGA TAT GC-3 ′ )-specifi c primers were used to amplify the ITS region, as described by White et al . [9] . The PCR was carried out under the following conditions: fi rst cycle at 95 ° C for 5 min, followed by 30 cycles at 95 ° C for 1 min, at 60 ° C for 30 s, and at 72 ° C for 1 min, with a fi nal extension step at 72 ° C for 10 min. The amplifi ed products were purifi ed using the QIAquick PCR Purifi cation Kit (Qiagen, Hilden, Germany) . Both strands of purifi ed amplicons were sequenced with an ABI Prism 3130 DNA analyzer (Applied Biosystems, Foster City, CA, USA) using primers for ITS1 and ITS4. The amplicons were sequenced and subjected to BLAST searches against the GenBank database (www. ncbi.nlm.nih.gov/genbank).
Molecular identifi cation of C. parapsilosis complex
Identifi cation of species comprising the C. parapsilosis group was achieved using PCR-restriction fragment length polymorphism (RFLP). Amplifi cation of the secondary alcohol dehydrogenase-encoding (SADH) gene was performed by PCR with primers previously described by Tavanti et al . [4] . Ban I digestion patterns of the SADH PCR products were used to discriminate C. parapsilosis sensu stricto , C. orthopsilosis , and C. metapsilosis . A 15 μ l sample was loaded and separated by electrophoresis using a 7.5% acrylamide gel which was stained in ethidium bromide solution (0.5 μ g/ml) and photographed under ultraviolet illumination. C. parapsilosis and C. metapsilosis were revealed by two and four band patterns, respectively, while C. orthopsilosis was detected by the presence of a non-digested band (716 bp) (Fig. 1) .
Secretory aspartic proteinase (SAPP) gene analysis
The synthetic oligonucleotides used as primers were: 5 ′ -AGT GGT CGT CAA ACC ACT CC-3 ′ and 5 ′ -GAC GGA AGC AAG CGA AAT AG-3 ′ ( SAPP1 ); 5 ′ -TTA CTT GCC TGA CAG CAT-3 ′ and 5 ′ -CGC ATA AGC GTG TCT CAA AA-3 ′ ( SAPP2 ); and 5 ′ -TAA TGC GTC TCA CTG GA-3 ′ and 5 ′ -AGA CCC ATG ACC CCT AG-3 ′ ( SAPP3 ) [4, 10] . DNA amplifi cation was performed using the following cycling parameters in a Perkin Elmer 9600 48 h. The wells were washed three times with 0.05% Tween-20 in PBS to remove non-adhered cells. Fungal cells that remained attached to the plastic surface were considered to have formed biofi lm . A semiquantitative measurement of C. parapsilosis biofi lm formation was obtained via the 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide (XTT) reduction assay. The colorimetric change was measured using a microtiter reader at 492 nm. Biofi lm production was considered as absent when the OD was equal and lower than values of wells containing XTT only.
Growth in TPN
Approximately 10 4 cells of each test microorganism were added to 10 ml of a commercial TPN solution in sterile plastic tubes. Tubes were incubated at 30 ° C and sampled at 0, 24, and 48 h. Each sample was inoculated onto Sabouraud dextrose agar (SDA) plates and the numbers of colony forming units (CFU) were counted at each time point.
Antifungal susceptibility testing
Antifungal susceptibility testing was performed by broth microdilution method according to the Clinical and Laboratory Standards Institute (CLSI) M27-A3 guidelines [15] . Of 42 strains, 40 (36 C. parapsilosis sensu stricto , three C. metapsilosis and one C. orthopsilosis ) retained viability at the time of antifungal susceptibility testing and were included in the assay. Fluconazole (Pfi zer Inc., Groton, Connecticut, USA), voriconazole (Pfi zer Inc., Sandwich, Kent, UK), caspofungin (Merck & Co., White House Station, New Jersey, USA), anidulafungin (Pfi zer Inc., Groton, Connecticut, USA) and amphotericin B ( Bristol-Myers Squibb Co., Middlesex, UK) were provided in standard powder forms by the respective manufacturers. As recommended by CLSI, antifungal stock solutions were prepared in water for fl uconazole and caspofungin and in dimethylsulphoxide (DMSO) for anidulafungin, voriconazole, and amphotericin B. Antifungal concentration ranges were as follows: fl uconazole and anidulafungin 64 -0.125 μ g/ml; voriconazole and amphotericin B 8 -0.015 μ g/ml; and caspofungin 16 -0.03 μ g/ml. The minimum inhibitory concentrations (MICs) were determined by visual reading at 24 and 48 h of incubation at 35 ° C. The MIC recorded was the lowest antifungal concentration reducing turbidity by approximately 50% (MIC-2) for all antifungals, with the exception of amphotericin B [15] . For amphotericin B, the lowest drug concentration that prevented any discernible growth (MIC-0) was recorded as the MIC [15] . Candida krusei ATCC 6258 and C. parapsilosis ATCC 22019 were included as quality controls in each test run [16] . Clinical breakpoints proposed for thermocycler (Perkin Elmer, Cetus, Norwalk, CT, USA): initial denaturation at 94 ° C for 4 min, followed by 30 cycles of denaturation at 94 ° C for 50 s, annealing at 54 ° C s for 50 s, and extension at 72 ° C for 50 s. A 7-min extension at 72 ° C was included at the end of the fi nal cycles. Then, 10 μ l PCR product was separated by electrophoresis using 2% (wt/vol) agarose. The gel was stained with ethidium bromide solution (0.5 μ g/ml) and photographed under ultraviolet illumination.
Extracellular proteolytic activity
Candida parapsilosis isolates were analyzed for secretory proteolytic activity on solid medium as described previously [11] , with minor modifi cations. The inducing medium contained 1.17% Yeast Carbon Base, 0.01% yeast extract, 0.2% bovine serum albumin (BSA), and 0.02 ppm bromphenol blue. The medium was prepared in citrate buffer (pH 4.5) and fi lter sterilized and then added to a solution of autoclaved 2% agar. Next, 10 μ l of each yeast suspension (10 6 cells/ml) was inoculated onto BSA agar plates and incubated at 30 ° C for 7 days. Proteolysis was determined by clarifi cation of the medium around the colony and the Pz values were calculated as described previously [12] . Briefl y, proteinase activity (Pz) was expressed as the ratio of the diameter of the colony to the diameter of the colony plus the precipitation zone. A Pz of 1.0 was evaluated as negative, 0.90 -0.99 as weak, 0.80 -0.89 as mild, and 0.70 -0.79 as strong.
Determination of lipolytic activity
Lipolytic activity was examined according to the method of Gacser et al . [13] , using colonies grown on rhodamine B plates (7 g/l Yeast Nitrogen Base [YNB], 20 ml/l olive oil, 50 ml/l fetal bovine serum [FBS] , and 1 ml/l 1 M rhodamine B). Approximately 10 μ l of each yeast suspension (10 6 cells/ml) was inoculated onto agar plates and incubated at 30 ° C for 7 days. Lipolytic activity was demonstrated by the presence of red-stained regions and lysis zones around the colonies.
Biofi lm formation
Biofi lm formation by C. parapsilosis complex isolates were quantifi ed by metabolic activity as previously described [14] . Polystyrene 96-well plates (Greiner bioone, Frickenhausen , Germany) were inoculated with 100 μ l FBS overnight and washed twice with sterile phosphatebuffered saline (PBS). C. parapsilosis cells were collected by centrifugation, washed twice with PBS, suspended at 10 6 cells/ml in RPMI 1640 medium, and 100 μ l suspensions of yeast were incubated at 37 ° C without shaking for 
Results
Of 42 C. parapsilosis complex isolates, three were identifi ed as C. metapsilosis and one as C. orthopsilosis . The distribution of the three species in different clinical samples is detailed in Table 1 and as noted most were isolated from urine (47.6%) and blood (21.4%) specimens. The distribution of the three species among nine blood isolates was 77.8% (7/9) C. parapsilosis sensu stricto and 22.2% (2/9) C. metapsilosis , with no isolates of C. orthopsilosis recovered from these samples. C. parapsilosis sensu stricto was isolated from patients of all age groups, whereas C. orthopsilosis and C. metapsilosis were isolated from elderly patients.
The sequences of ITS region of three C. metapsilosis isolates (length of analyzed sequences: 403 -530 nts) and one C. orthopsilosis strain (length of analyzed sequence: 442 nts) were identical and showed 100% identity with the corresponding sequences. The ITS region sequences of all strains showed similarities with the corresponding sequences of the reference C. parapsilosis (FJ872015.1), C. orthopsilosis (EU564208), and C. metapsilosis (EU564207.1) strains. Similar results were found by SADH-RFLP.
All isolates grew in TPN, with some C. parapsilosis and one C. metapsilosis strain reaching their maximum concentration within 48 h. Colony counts of the C. orthopsilosis strain, two of the three C. metapsilosis strains, and nine of the 39 C. parapsilosis sensu stricto strains did not increase prominently after 24 h ( Table 2) .
A total of 11 (26.2%) of the 42 C. parapsilosis complex isolates were biofi lm-positive (Table 2) , all of which were C. parapsilosis sensu stricto . Urine isolates were more likely to form biofi lms than isolates from other sources.
Lipase activity was detected in 33.3% (14/42) of isolates (Table 2) . Urine-derived isolates had the most lipase activity. A total of 13/42 (31%) C. parapsilosis complex isolates were found to produce acid proteinase, six (46%) of which had strong activity (Table 2) . Isolates from specimens other than blood possessed strong proteinase activity. None of the C. metapsilosis or C. orthopsilosis isolates exhibited proteinase activity, although all isolates possessed genes encoding the enzymes ( SAPP1 -3 ; Fig. 2) .
MIC results obtained for isolates of C. parapsilosis sensu stricto are shown in Table 3a and those recorded for C. metapsilosis or C. orthopsilosis are depicted in Table 3b . The isolates of C. parapsilosis sensu stricto appeared highly susceptible to antifungal drugs in general, only one isolate being dose-dependent susceptible to fl uconazole. All remained susceptible to voriconazole, caspofungin, and anidulafungin (Table 3a) . In general, the MICs obtained for the C. metapsilosis and C. orthopsilosis isolates did not display differences as compared to those for C. parapsilosis sensu stricto (Table 3b ).
Discussion
Candida parapsilosis is a ubiquitous microorganism in the natural environment. Its virulence is associated with its capacity to adhere to plasic surfaces, and consequently, to the development of candidemia related to catheters [18, 19] . Recently, Tavanti et al . [4] described two new species belonging to the C. parapsilosis complex, C. metapsilosis and C. orthopsilosis . C. metapsilosis was less virulent in vitro as compared to C. orthopsilosis and C. parapsilosis sensu stricto [20, 21] . These two new species may inhabit important niches in certain patient populations, thus stressing the need for continued surveillance in each country to monitor the prevalence and distribution of the members of the complex [22] . Defi ning the virulence determinants of this new species will help to understand their pathogenic characteristics.
After SADH PCR-RFLP identifi cation of C. parapsilosis complex isolates, the identity of all isolates was confi rmed by PCR-based sequencing using primers for ITS1 and ITS4. We found that 2/3 C. metapsilosis were recovered from blood, and only one C. orthopsilosis was obtained from an ear sample. Lockhart et al . collected isolates of C. parapsilosis between 2001 and 2006 as part of the ARTEMIS Global Surveillance study [6] . C. parapsilosis accounted for 91.3% of the isolates, while 6.1% were C. orthopsilosis and 1.8% were C. metapsilosis . In addition, C. orthopsilosis increased longitudinally during this surveillance study. A population-based study from Spain found that C. metapsilosis comprised 6.9% and C. orthopsilosis 5.7% of all C. parapsilosis complex isolates collected between 2002 and 2003 [8] . Silva et al . reported 91.4% C. parapsilosis , 2.3% C. orthopsilosis , and 2.9% C. metapsilosis in their study [22] . New species were found in biological samples other than blood. Lockhart et al .
[6] identifi ed, among 75 yeast isolates from Turkey, one C. ortopsilosis and two C. metapsilosis strains, but there was no information regarding the clinical samples from which they were recovered or regional distribution. In our previous study, between October 2005 and July 2009, 98.5% (67/68) of the isolates we identifi ed were C. parapsilosis sensu stricto , and 1.5% (1/68) was identifed as C. orthopsilosis , whereas no C. metapsilosis isolates were detected. The strain identifi ed as C. orthopsilosis was from a urine specimen, and all the blood isolates were C. parapsilosis sensu stricto [24] . C. metapsilosis has been reported to be recovered from clinical samples only rarely [25] . Interestingly, C. metapsilosis was increasingly found during the study period in our hospital. These new species are ubiquitous in nature, and their potential for infection is not well known. Ghannoum et al . [26] isolated C. metapsilosis from oral swabs, suggesting that this species could also be a human commensal microorganism. Ge et al . [12] reported a high frequency of isolation of C. metapsilosis (35.5%) from skin samples. Whether the isolation of new species reveals geographic regional differences in various clinical samples will be evaluated by future studies. In light of these fi ndings, it is likely that new species will increasingly become the agents of future infections.
C. parapsilosis can be a member of the human microbiome, but possesses the ability to grow in parenteral nutrition solutions, to form biofi lms on catheters, to spread by hand carriage, and to persist in the nosocomial environment [3] . Although C. metapsilosis is less virulent than C. parapsilosis sensu stricto and C. orthopsilosis , some authors have reported the isolation of this species from bloodstream infections (BSI) [8, 27, 28] . The ability of C. albicans and other pathogens to grow in parenteral nutrition formulations is known and is considered to be a risk factor for the development of catheter-related BSI in patients receiving parenteral nutrition [29] . Swindel et al . [2] showed that parenteral lipid emulsion induced germination and supported the growth of C. albicans , increasing biofi lm formation on medical catheter surfaces. In this study, viable counts of all strains increased at least two log in TPN after 24 h incubation. After 48 h, slight reduction was seen in colony counts of the C. orthopsilosis strain, but viable counts of C. parapsilosis sensu stricto and C. metapsilosis strains increased. C. orthopsilosis was isolated from an ear-derived sample. These fi ndings should be confi rmed, but the characteristics of biofi lm formation on catheter materials and growth in TPN could be virulence factors of C. orthopsilosis and C. metapsilosis , as much as C. parapsilosis sensu stricto .
C. parapsilosis biofi lms tend to be thinner, less structured, and consist almost exclusively of aggregated blastospores [30] . Interestingly, biofi lm formation by C. parapsilosis has been described as being strongly straindependent [31, 32] . Additionally, two newly identifi ed species of the C. parapsilosis complex, C. metapsilosis and C. orthopsilosis , have also been shown to be capable of forming biofi lms on silicone elastomer discs [33] . Biofi lms are readily formed by C. parapsilosis cells grown in media containing high glucose and lipid concentrations, which is analogous to BSI in patients receiving parenteral nutrition. Notably, biofi lm-defi cient C. parapsilosis lipase mutants were less virulent in tissue culture infection models and also in mice [20] . A total of 11 (26.2%) of the 42 C. parapsilosis complex isolates were biofi lm-positive. C. parapsilosis sensu stricto was the only species to form biofi lms in some studies [7, 25, 34] . In contrast, Lattif et al . [33] showed that all three species were able to form biofi lms using an in vitro model of silicone catheter discs. Discrepancies between these studies may be due to the use of different strains and methods.
Secretion of hydrolytic enzymes, such as aspartic proteinases, phospolipases, and lipases has been associated with C. parapsilosis virulence. Gacser and his colleagues [20] showed that the reduction in damage to reconstituted human tissues (RHT) by ebelactone B and pepstatin A indicated that lipases and aspartic proteinases are involved in the pathogenesis of disease caused by C. parapsilosis . It was also observed that C. orthopsilosis induced a high level of macrophage damage, similar to C. parapsilosis sensu stricto isolates, while C. metapsilosis exhibited the lowest cytotoxicity.
Lipases are involved in both the hydrolysis and synthesis of triacylgycerols. For C. parapsilosis , the presence of the CpLIP1 and CpLIP2 genes has been reported, with the latter known to encode for an active protein [33] . Recently, Gacser et al . [20] demonstrated that a lipase inhibitor signifi cantly reduced tissue damage during C. parapsilosis infection of RHT, and that CpLIP1 and CpLIP2 mutants formed thinner, less complex biofi lms and had reduced growth in lipid-rich media. In our study, lipase activity was detected in 33.3% of isolates. Lipase enzyme activity of the strains of these new species is needed to be studied in a large number of strains.
In C. parapsilosis , three orthologous genes have been found to-date, i.e., SAPP1 -3 . Of the respective proteins, only Sapp1p and Sapp2p have been studied extensively on an enzymological level. The SAPP3 gene product has not yet been isolated or cloned [36] . In addition, Horv á th et al . [37] demostrated that the SAPP1 gene has two copies in the C. parapsilosis genome ( SAPP1a and SAPP1b ). They showed that the C. parapsilosis Δ Δ sapp1a-Δ Δ sapp1b mutant was unable to escape human immune system components. Silva et al . [31] showed that the expression of SAP genes by C. parapsilosis was straindependent, with SAPP1 being expressed by all isolates causing infections. In our study, 31% of the C. parapsilosis sensu stricto isolates were found to be acid proteinase producers, with urine-derived isolates having higher SAP activities. None of the C. metapsilosis or C. orthopsilosis strains demonstrated SAP enzyme activity. Lin et al . [38] reported that group I isolates showed strong or moderately strong proteinase activity, whereas groups II and III isolates had low proteinase activity. Tavanti et al . [39] determined that 33.9% of C. parapsilosis sensu stricto strains produced proteinase, the higher producers being recovered from blood and mucus specimens. In addition, expression of some virulence factors varied among strains isolated from different geographical 490. Tosun et al. regions. Sabino et al . [40] showed that C. orthopsilosis were SAP producers, whereas C. metapsilosis were not. Hensgens et al . [41] found fi ve isolates (40%) of C. metapsilosis isolates were proteinase producers. In another study, [12] some non-blood C. parapsilosis and C. metapsilosis isolates exibited higher proteinase activities. Reasons for the variability between our study and others may be due to method or strains isolated from different geographical samples. All isolates had SAPP1 -3 genes. The in vivo expression of these genes in new species should be evaluated in infection models. We also investigated the antifungal susceptibility profi les of our strains. With the exception of one fl uconazoledose-dependent susceptible strain of C. parapsilosis sensu stricto , all isolates exhibited low in vitro MICs and were susceptible to voriconazole, caspofungin, and anidulafungin using C . parapsilosis -specifi c CLSI interpretive MIC breakpoints [17] . We also compared the susceptibility profi les of C. parapsilosis sensu stricto isolates to those of C. metapsilosis and C. orthopsilosis and found that their MICs were not signifi cantly different as compared to those generated for C. parapsilosis sensu stricto . Moreover, using the breakpoints proposed for C. parapsilosis for interpretation of the results of C. metapsilosis and C. orthopsilosis , these two species also appear susceptible to the noted antifungal drugs. However, our data remain inadequate for justifi cation of any comparative conclusion on in vitro susceptibility patterns since the number of the C. metapsilosis and C. orthopsilosis strains included in the study is very small (n-3 and 1, respectively).
Antifungal susceptibility profi les of C. parapsilosis complex strains have been previously investigated in various studies [42 -45] , but the results in most of these [44, 45] refer to C. parapsilosis complex rather than individual species of C. parapsilosis complex. In these studies, including ARTEMIS disk antifungal surveillance program (comprising strains from 124 medical centers worldwide), high levels of susceptibility to both fl uconazole and voriconazole, as well as relatively low MICs of caspofungin, micafungin, and anidulafungin ( Յ 2 μ g/ml) have been reported, suggesting that C. parapsilosis strains are, in generally, highly susceptible to azoles and echinocandins [42 -45] . These results are in accordance with the high levels of azole and echinocandin susceptibility that we have detected for our strains.
There are limited antifungal susceptibility data published for isolates of the individual species that comprise the C. parapsilosis complex [22, 23, 27, 44, 46] . Furthermore, the recent modifi cations in species-specifi c MIC breakpoints render the resistance rates reported in different studies diffi cult to compare. In general, reduced susceptibility and relatively high MICs of fl uconazole ( Ն 8 μ g/ml) have been described for some but a few isolates of species of C. metapsilosis [27, 41] and C. orthopsilosis [25, 47] . High fl uconazole and echinocandin MICs ( Ն 8 μ g/ml) have been detected in a low number of strains of C. parapsilosis sensu stricto as well (46). The azole and echinocandin MICs generated in our hands for our strains belonging to C. metapsilosis and C. orthopsilosis are relatively low and similar to those obtained for C. parapsilosis sensu stricto. However and as noted previously, testing more isolates is required for determination of virtual rates of resistance among the strains of the two former species.
Susceptibility of C. parapsilosis complex strains to amphotericin B has also been studied by various investigators [22, 23, 25, 27, 41, 45] . However, interpretive criteria for assessment of in vitro susceptibility test results for amphotericin B has been problematic so far against all Candida spp., including C. parapsilosis and clinical MIC breakpoints are not yet available. Using the epidemiological cutoff values, strains with amphotericin B MICs of Յ 2 μ g/ml are now classifi ed as wild-type strains [17] and all of our strains fall into this category (Table 3) . Amphotericin B MICs reported by other investigators of isolates of C. parapsilosis complex also appear, in general, to fall within the category of wild-type in general [22, 23, 25, 27, 41, 45] .
In the present study, C. parapsilosis sensu stricto was recovered from all types of clinical samples, but interestingly, we isolated more C. metapsilosis strains as compared to those of C. orthopsilosis which differs from other studies [6, 23, 46] . To the best of our knowledge, this is the fi rst study where lipase activity has been evaluated for the C. parapsilosis complex. Differences in virulence factors between species could not be determined at a statistically signifi cant level because of the small numbers of the newly described isolates. It is not yet clear whether these species pose a special risk for some patient groups or if there are regional disparities. The virulence properties of these new species should be tested in a wider collection of isolates. Virulence characterization of the new species will guide treatment options against them.
